GAUDIUMIVFBSEGaudium IVF and Women Health LtdMinimalNeutral
Announced Fri, 15 May · 20:41 IST

Monitoring Agency Report for quarter ended March 31, 2026

GAUDIUMIVF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹108.00
prior close
₹106.01
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-2.2-2.6-3.4-0.4+4.6+7.4+5.6+11.8+8.1-2.1-1.3+38.1
Up moveDown movePending
AI summary

Gaudium IVF filed its first Monitoring Agency Report for the IPO completed in February 2026 (₹90 crore fresh issuance + ₹75 crore offer for sale). Of the ₹90 crore gross proceeds, ₹7.72 crore was used for issue expenses, leaving ₹82.28 crore in net proceeds. During Q4 FY26, only ₹8.69 crore was deployed (₹0.97 crore towards general corporate purposes and ₹7.72 crore for issue expenses). As of March 31, 2026, ₹81.31 crore remains unutilized, parked in HDFC Bank fixed deposits earning 7.20–7.27% interest and current accounts. The ₹50 crore allocated for new IVF centre expansion and the ₹20 crore earmarked for debt repayment have not been deployed yet. The monitoring agency (Infomerics Valuation) confirms no deviations from the offer document objects, with the delay attributed to commercial and operational considerations.

Likely market impact

No red flags for investors — the monitoring agency certifies proper utilization aligned with the prospectus. However, deployment delays in core capital expenditure (new IVF centres) and debt repayment suggest the company is not in a rush to deploy IPO proceeds, which could delay revenue growth and interest savings. The unutilized funds are safely parked in FDs, mitigating concern about idle cash.